Meredith S. Manning was appointed Director of Unicycive Therapeutics, Inc., effective October 1, 2026. As of November 6, 2026, Unicycive Therapeutics, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 6, 2026 to September 29, 2026, naming 1 appointment and 1 departure (Form 8-K, September 29, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Unicycive Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Unicycive Therapeutics, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-06 to 2026-09-29. They name 2 people, with 1 appointment and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Unicycive Therapeutics, Inc. files it.
Also on the record for Unicycive Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G/A, by Nantahala Capital Management, LLC | 9.99% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Vivo Opportunity Fund Holdings, L.P. | 9.99% of the class | 5%+ stakes | Source |
| July 30, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.3% of the class | 5%+ stakes | Source |
| July 8, 2026 | Stake report, Schedule 13G/A, by Millennium Management LLC | 1% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by RA Capital Management, L.P. | 9.9% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by RA Capital Management, L.P. | 9.9% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Nantahala Capital Management, LLC | 9.99% of the class | 5%+ stakes | Source |
| February 10, 2026 | Stake report, Schedule 13G/A, by Octagon Capital Advisors LP | 4.7% of the class | 5%+ stakes | Source |
| January 23, 2026 | Stake report, Schedule 13G, by Integrated Core Strategies (US) LLC | 5.5% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Great Point Partners, LLC | 4.51% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Nantahala Capital Management, LLC | 9.99% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Octagon Capital Advisors LP | 5.7% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Unicycive Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Unicycive Therapeutics, Inc. and the records around it.
Unicycive Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- Octagon Capital Advisors LP also filed stake reports on 8 other companies: Precision BioSciences, Inc. (Nov 2026), Context Therapeutics Inc. (Jul 2026), Corbus Pharmaceuticals Holdings, Inc. (May 2026)
- Great Point Partners, LLC also filed stake reports on 14 other companies: LeonaBio, Inc. (Nov 2026), Research Alliance Corporation III (Sep 2026), JATT III Acquisition Corp (Sep 2026)
- Vivo Opportunity Fund Holdings, L.P. also filed stake reports on 20 other companies: ArriVent BioPharma, Inc. (Oct 2026), Clene Inc. (Aug 2026), Compass Therapeutics, Inc. (Aug 2026)
Watch Unicycive Therapeutics, Inc.
Get an email when Unicycive Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Unicycive Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Unicycive Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Unicycive Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 18 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-29 | In | Director | 2026-10-01 | 8-K, 2026-09-29 | |
| 2026-04-06 | Out | Director | 8-K, 2026-04-06 |
Who leads Unicycive Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Meredith S. Manning, appointed, effective 2026-10-01 (filed 2026-09-29).
New leaders reset buying decisions — get the Full Report on Unicycive Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Unicycive Therapeutics, Inc., with the record behind each one.
Find candidates like Director at Unicycive Therapeutics, Inc.Every change, in the filing's words
Appointed: Meredith S. Manning, Director, effective 2026-10-01
On September 28, 2026, Unicycive Therapeutics, Inc. (the "Company") appointed Meredith S. Manning as an independent director on the Company's board of directors, effective October 1, 2026.
- Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
- Ms. Manning will serve on each of the Audit, Compensation and Nominating and Corporate Governance Committees, and also as the Chairperson of the Nominating and Corporate Governance Committee.
- Meredith S. Manning, M.B.A., has more than 25 years of global biopharmaceutical experience.
- Most recently, she served as Chief Commercial Officer of Soleno Therapeutics, Inc. from 2024 until its acquisition by Neurocrine Biosciences, Inc. in 2026.
- At Soleno, she built the commercial organization from inception and led the U.S. launch of VYKAT XR, the first FDA-approved treatment for hyperphagia in Prader-Willi syndrome.
- As a member of the executive team, she also played a key role in asset evaluation, lifecycle planning, and due diligence, and led the selection of ex-U.S. distribution partners.
- Previously, Ms. Manning served as President, The Americas, and a voting member of the U.S. Board of Directors of PharmaEssentia Corporation from 2020 to 2023.
- In this role, she built the U.S. company from the ground up, with general management and P&L responsibility for all U.S. functions.
Departing: Gaurav Aggarwal, Director
On April 6, 2026, Gaurav Aggarwal, a director of Unicycive Therapeutics, Inc. (the "Company"), resigned from the Board of Directors of the Company.
- Dr. Aggarwal's resignation was not a result of any disagreement with the Company or its management or Board on any matter related to the Company's operations, policies, or practices.
Tools for this story
Each opens in a new tab, filled in for Unicycive Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.